IL126768A0 - Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy - Google Patents

Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Info

Publication number
IL126768A0
IL126768A0 IL12676897A IL12676897A IL126768A0 IL 126768 A0 IL126768 A0 IL 126768A0 IL 12676897 A IL12676897 A IL 12676897A IL 12676897 A IL12676897 A IL 12676897A IL 126768 A0 IL126768 A0 IL 126768A0
Authority
IL
Israel
Prior art keywords
inhibitors
enhance
protein kinase
radiation therapy
clinical efficacy
Prior art date
Application number
IL12676897A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL126768A0 publication Critical patent/IL126768A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12676897A 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy IL126768A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,738 US6232299B1 (en) 1996-05-01 1997-04-30 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
PCT/US1997/007801 WO1997040842A1 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Publications (1)

Publication Number Publication Date
IL126768A0 true IL126768A0 (en) 1999-08-17

Family

ID=26688914

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12676897A IL126768A0 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Country Status (15)

Country Link
US (3) US6232299B1 (pt)
EP (1) EP0914135A4 (pt)
JP (1) JP2000510828A (pt)
KR (1) KR20000065223A (pt)
AU (1) AU718098B2 (pt)
BR (1) BR9710704A (pt)
CA (1) CA2253263A1 (pt)
CZ (1) CZ344398A3 (pt)
EA (1) EA199800971A1 (pt)
HU (1) HUP0100285A3 (pt)
IL (1) IL126768A0 (pt)
NO (1) NO985065L (pt)
NZ (1) NZ332563A (pt)
PL (1) PL330862A1 (pt)
WO (1) WO1997040842A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
WO2005009961A2 (en) 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
RU2405784C2 (ru) * 2003-10-15 2010-12-10 Оси Фармасьютикалз, Инк. Имидазопиразины в качестве ингибиторов тирозинкиназ
EP1740591B1 (en) 2004-04-02 2009-06-17 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US20060228734A1 (en) * 2005-03-18 2006-10-12 Applera Corporation Fluid processing device with captured reagent beads
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
BRPI0614809A2 (pt) * 2005-08-09 2011-04-12 Johannes Gutenberg Universitaet Mainz sensibilização de cánceres de pulmão resistentes a fármaco a inibidores de proteìna cinase
CA2622867A1 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
CA2696402A1 (en) 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US8227202B2 (en) * 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2010135608A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
SG192669A1 (en) 2011-02-11 2013-09-30 Glaxosmithkline Ip Dev Ltd Cathepsin c inhibitors
WO2012173841A1 (en) * 2011-06-07 2012-12-20 Dana-Farber Cancer Institute, Inc. Biomarker for pkc-iota activity and methods of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4990519A (en) 1988-10-24 1991-02-05 Merrell Dow Pharmaceuticals Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5204370A (en) 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
BR9106118A (pt) * 1990-11-02 1993-03-02 Sphinx Pharma Corp Antraquinona substituida,composicao famaceutica e processo para inibir quinase c de proteina e,uso de um composto
US5141957A (en) 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
JPH06510280A (ja) * 1991-08-22 1994-11-17 スフィンクス・ファーマスーティカルズ・コーポレーション タンパクキナーゼｃ阻害および新規化合物バラノール
US5216014A (en) 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
CA2174431C (en) 1993-10-18 2005-12-06 Tomas Hudlicky Synthesis of sphingosines
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JPH07238044A (ja) 1993-12-07 1995-09-12 Eli Lilly & Co ビスインドリルマレイミドの改良合成法
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP0763041A1 (en) * 1994-06-01 1997-03-19 Novartis AG Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5432198A (en) * 1994-08-18 1995-07-11 Sphinx Pharmaceuticals Corporation Vicinal-substituted carbocyclic compounds as therapeutic agents
US5616577A (en) 1994-08-25 1997-04-01 Smithkline Beecham Corporation Protein Kinase C inhibitor

Also Published As

Publication number Publication date
NO985065D0 (no) 1998-10-30
JP2000510828A (ja) 2000-08-22
PL330862A1 (en) 1999-06-07
BR9710704A (pt) 1999-08-17
NO985065L (no) 1998-12-28
NZ332563A (en) 2000-08-25
HUP0100285A2 (hu) 2001-09-28
KR20000065223A (ko) 2000-11-06
WO1997040842A1 (en) 1997-11-06
EA199800971A1 (ru) 1999-04-29
US6232299B1 (en) 2001-05-15
AU3000297A (en) 1997-11-19
AU718098B2 (en) 2000-04-06
EP0914135A1 (en) 1999-05-12
CA2253263A1 (en) 1997-11-06
US6486179B2 (en) 2002-11-26
CZ344398A3 (cs) 1999-07-14
US6288053B1 (en) 2001-09-11
EP0914135A4 (en) 2001-01-24
US20010001791A1 (en) 2001-05-24
HUP0100285A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
IL126768A0 (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
EP0764030A4 (en) USE OF AUTOANTIBODIES FOR ANTI-TUMOR THERAPY AND PROPHYLAXIS
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
HUP0200773A3 (en) Methods of inducing cacer cell death and tumor regression
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
PL330235A1 (en) Derivatives of spiropiperidine and their application as therapeutic agents
ID18679A (id) Penggunaan terapi lanjutan
PL334662A1 (en) Terbenzimidazoles (inhibitors of topisomerase) useful in medical therapy
HU9801634D0 (en) Genetically modified cells and their use in prevention or therapy of disease
GB9412711D0 (en) Medical use of bromelain
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
GB9708067D0 (en) Rapid and long lasting biocidal system and its use to the treatment of hard surfaces
DE4391805T1 (de) Körpertherapiekissen
ZA93212B (en) Enzyme castration of animal and tumor treatment
ZA95508B (en) Use of flavolignans as adjuvants in tumour therapy
AU2001271257A1 (en) Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
IL132531A0 (en) Detection and therapy of tumors
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
KR940005082U (ko) 전신 쑥뜸기
EP1001966A4 (en) SENESCENCE GENE AND ITS USE IN THE TREATMENT OF CANCER AND OTHER DISEASES
GB9905307D0 (en) Therapy and use of compounds in therapy